Gyre Therapeutics Inc. (GYRE) — Cash Flow Quality Index
Gyre Therapeutics Inc. (GYRE) has a Cash Flow Quality Index of 0.79x as of September 2025. Operating cash flow of $4.68 Million is below net income of $5.94 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Gyre Therapeutics Inc. operating cash flow efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Gyre Therapeutics Inc. Cash Flow Quality Index (2006–2025)
Historical Cash Flow Quality Index for Gyre Therapeutics Inc. across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check GYRE capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Gyre Therapeutics Inc. (2006–2025)
Year-by-year earnings quality comparison for Gyre Therapeutics Inc.. For live market cap and the full company financial profile, see Gyre Therapeutics Inc. stock valuation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | $1.01 Million | $9.88 Million | ▲ +150.3% |
| 2024 | -0.20x | $-3.64 Million | $17.90 Million | ▼ -108.2% |
| 2022 | 2.47x | $10.68 Million | $4.31 Million | ▼ -80.5% |
| 2010 | 12.69x | $138.30 Million | $10.90 Million | ▲ +368.9% |
| 2006 | -4.72x | $-9.89 Million | $2.10 Million | — |